ArticleImmunity2012
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments.
Article in Immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 1 synthesis or guideline pooled it, 327 citations in OpenAlex.
- Knowledge mapping of DNGR-1 on dendritic cells in immunotherapy: a review and bibliometric study.Frontiers in immunology · 2026Pooled it
- Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.Vaccines · 2026Review
- A Rarefaction Approach to Identify Local Introgression in a Three Population Tree.bioRxiv : the preprint server for biology · 2026Article
- Roles of efferocytosis in wound repair: Process, cells, and signals.Genes & diseases · 2026Review
- Perforin-2 enhances antigen-specific CTL immune response by promoting cross presentation.Cell death & disease · 2026Article
- Directed evolution of Clec12a-binding peptides using mammalian-expressed recombinant protein.Biochemistry and biophysics reports · 2026Article
- Dendritic Cells in the Gastrointestinal System: Division of Labor, Plasticity, and Niche-Specific Adaptation.Immunological reviews · 2026Review
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- DNGR-1 signalling limits dendritic cell activation for optimal antigen cross-presentation.The EMBO journal · 2025Article
- Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity.The Journal of pharmacology and experimental therapeutics · 2025Review
- Global transcriptional reprogramming by cytomegalovirus infection suppresses MHC class II antigen presentation while enhancing migration machinery in murine dendritic cells.Microbial genomics · 2025Article
- Review
- DNGR-1 regulates proliferation and migration of bone marrow dendritic cell progenitors.The Journal of experimental medicine · 2025Article
- PTPN2 Negatively Regulates Macrophage Immune Responses and Cellular Bioenergetics.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Degradation rather than disassembly of necrotic debris is essential to enhance recovery after acute liver injury.Cellular and molecular life sciences : CMLS · 2025Article
- Shared pathway of WDFY4-dependent cross-presentation of immune complexes by cDC1 and cDC2.The Journal of experimental medicine · 2025Article
- Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers.Molecular cancer · 2025Article
- MAIT cells protect against sterile lung injury.Cell reports · 2025Article
- Targeting NINJ1-mediated cell rupture to treat inflammatory diseases.Molecular medicine (Cambridge, Mass.) · 2025Review
- Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.NPJ vaccines · 2025Review
122 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
27 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system must distinguish viable cells from cells damaged by physical and infective processes. The damaged cell-recognition molecule Clec9A is expressed on the surface of the mouse and human dendritic cell subsets specialized for the uptake and processing of material from dead cells. Clec9A recognizes a conserved component within nucleated and nonnucleated cells, exposed when cell membranes are damaged. We have identified this Clec9A ligand as a filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins. We have determined the crystal structure of the human CLEC9A C-type lectin domain and propose a functional dimeric structure with conserved tryptophans in the ligand recognition site. Mutation of these residues ablated CLEC9A binding to damaged cells and to the isolated ligand complexes. We propose that Clec9A provides targeted recruitment of the adaptive immune system during infection and can also be utilized to enhance immune responses generated by vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.